Results 31 to 40 of about 7,263 (276)

Netupitant/palonosetron (NEPA; Akynzeo®) combination in prevention of the nausea and vomiting in patients with breast cancer receiving anthracyclinbased chemotherapy

Опухоли женской репродуктивной системы, 2023
Chemotherapy-induced nausea and vomiting is a common problem during cancer treatment, especially in breast cancer patients with anthracycline/cyclophosphamide (ас) chemotherapy.
A. G. Kedrova, A. I. Berishvili
doaj   +1 more source

Pharmacokinetics, safety, and efficacy of mixed formulation of fosrolapitant and palonosetron (HR20013) in combination with dexamethasone in patients with solid tumors scheduled for highly emetogenic cisplatin-based chemotherapy: a phase I trial [PDF]

BMC Med
Zhao Y, Ma Y, Yin T, Qin Z, Liu L, Kong G, Zhang R, Huang Y, Zhang L, Zhao H.   +9 more
europepmc   +3 more sources

Applicability of the National Comprehensive Cancer Network/Multinational Association of Supportive Care in Cancer Guidelines for Prevention and Management of Chemotherapy-Induced Nausea and Vomiting in Southeast Asia: A Consensus Statement. [PDF]

, 2017
A meeting of regional experts was convened in Manila, Philippines, to develop a resource-stratified chemotherapy-induced nausea and vomiting (CINV) management guideline. In patients treated with highly emetogenic chemotherapy in general clinical settings,
Abdullah, Matin M, Chan, Alexandre, Ishak, Wan Zamaniah B Wan, Kanesvaran, Ravindran, Ong-Cornel, Annielyn B, Villalon, Antonio H   +5 more
core   +2 more sources

A phase II trial of netupitant/palonosetron for prevention of chemotherapy-induced nausea/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation

Journal of Oncology Pharmacy Practice, 2023
Objective: The purpose of this study was to investigate the efficacy and safety of netupitant/palonosetron (NEPA) for the prevention of chemotherapy-induced nausea and vomiting (CINV) for hematopoietic cell transplantation (HCT) patients receiving BEAM ...
J. Bubalo, J. Radke, K. Bensch, A. Chen, S. Misra, R. Maziarz   +5 more
semanticscholar   +1 more source

5-hydroxytryptamine (5-HT) cellular sequestration during chronic exposure delays 5-HT₃ receptor resensitization due to Its subsequent release [PDF]

, 2014
The serotonergic synapse is dynamically regulated by serotonin (5-hydroxytryptamine (5-HT)) with elevated levels leading to the down-regulation of the serotonin transporter and a variety of 5-HT receptors, including the 5-HT type-3 (5-HT(3)) receptors ...
Aapro, Ahern, Amy Alexander, Andrew J. Samson, Bearcroft, Bertrand, Bertrand, Bhattacharyya, Boyd, Chanrion, Chen, Chen, Christopher Moffat, Christopher N. Connolly, Connolly, Craig, Faerber, Freeman, Galligan, Guthrie, Hagbom, Hanley, Hansen, Hothersall, Huang, Ilegems, J. Daniel Hothersall, Jiménez-Trejo, Karen A. Bollan, Kittler, Kondaurova, Lau, Lee, Linder, Liu, Liu, Lummis, McKinnon, Mercado, Minami, Mnie-Filali, Muchatuta, Niesler, Riad, Rojas, Schlag, Spiller, Stratz, Tao-Cheng, Turvill, Vikenes, Wade, Wesseldijk, Whalen, Yasuda   +54 more
core   +3 more sources

A comparison of prophylactic antiemetic therapy with palonosetron and dexamethasone as single-agents or in combination in adult patients undergoing laparoscopic surgery: A randomized trial

International Journal of Critical Illness and Injury Science, 2023
Background: The incidence of postoperative nausea and vomiting (PONV) is quite high after laparoscopic surgeries. This study endeavors to compare the efficacy of the combination of palonosetron and dexamethasone with that of either drug alone in the ...
Neha Sadhoo, J. Prakash, Vishwanath Kumar, R. Kharwar, Sabih Ahmad, Bijaya Kumar Sethi   +5 more
semanticscholar   +1 more source

Every‐other‐day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the “Rete Ematologica Pugliese”

Cancer Medicine, 2020
Background Compared with older 5‐HT3 receptor antagonists, palonosetron requires fewer drug administrations to prevent chemotherapy‐induced nausea and vomiting (CINV) following multiple‐day chemotherapy.
Nicola Di Renzo, Lorella Melillo, Fernando Porretto, Michela Dargenio, Vincenzo Pavone, Domenico Pastore, Patrizio Mazza, Donato Mannina, Anxur Merenda, Nicola Cascavilla, Giuseppina Greco, Rosella Matera, Erminio Bonizzoni, Luigi Celio, Maurizio Musso   +14 more
doaj   +1 more source

Comparison of palonosetron with ondansetron in prevention of postoperative nausea and vomiting in patients receiving intravenous patient-controlled analgesia after gynecological laparoscopic surgery [PDF]

Korean Journal of Anesthesiology, 2013
BackgroundPostoperative nausea and vomiting (PONV) are common complications after anesthesia and surgery. This study was designed to compare the effects of palonosetron and ondansetron in preventing PONV in high-risk patients receiving intravenous opioid-
Yu Yil Kim, Soo Yeong Moon, Dong Un Song, Ki Hyun Lee, Jae Wook Song, Young Eun Kwon   +5 more
doaj   +1 more source

Efficacy and safety analysis of dexamethasone + palonosetron in prevention of post-embolization syndrome after D-TACE: A retrospective study

Medicine, 2023
To investigate the efficacy and safety of dexamethasone + palonosetron in the prevention of post-embolization syndrome after drug-eluting beads transcatheter arterial chemoembolization (D-TACE).
Haohao Lu, Chuansheng Zheng, B. Liang, X. Xia   +3 more
semanticscholar   +1 more source

All Eyes on Me, Please: Ocular Palonosetron for the Cancer Patient with Nausea and Vomiting

Journal of Pharmacology and Experimental Therapeutics, 2023
The March issue of the Journal of Pharmacology and Experimental Therapeutics offers an interesting read on palonosetron for managing nausea and vomiting in beagle dogs treated with the anticancer agent cisplatin (Levijoki et al., 2023).
G. Minotti
semanticscholar   +1 more source